Kirsten is a biopharmaceutical advisor who works with leaders in healthcare helping to develop business practices that lead to affordable access to medicines, positive public perception, and sustained investment in scientific advancement. her guidance is grounded in analytics and empirical evidence and a keen understanding of how the actors in the life sciences respond to reimbursement and regulation.
Kirsten was on the leadership team of Pfizer Inc’s $30 billion global innovative pharmaceutical business, where she led Strategy and Business Evaluation. Previously, Kirsten led Pfizer’s Global Policy team where she built a team dedicated to policy impact analytics. She is an Aspen Institute Health Innovator Fellow, and a consultant to life sciences companies, acting as a senior advisor to Charles River Associates and DLA Piper. She is a founder of the Preparedness and Treatment Equity Coalition and Board member Aequitas Health.
